With passion and exceptional technologies,
experts in CMC research support the creation of outstanding and innovative drugs.
SPERA PHARMA was established as a spin-out of Takeda Pharmaceutical Company by Chemistry, Manufacturing and Controls (CMC) research experts, who were already responsible for delivering numerous new drugs to high global acclaim.
READ MOREWith passion and exceptional technologies,
experts in CMC research support the creation of outstanding and innovative drugs.
SPERA PHARMA has inherited and is deepening further the various technologies and know-how that have been cultivated through research and development and practical use in Takeda Pharmaceuticals.
READ MOREIntroduction to the equipment and facilities of SPERA PHARMA that form our world class technology.
READ MORESPERA PHARMA is a pharmaceutical CMC R&D contract company spun out from the CMC Research Division of Takeda Pharmaceutical Co., Ltd. in July 2017.
2026.05.15
「Discovery & Development Europe 2026(15–16 June)」Exhibition Information
2026.05.08
INTERPHEX WEEK TOKYO 2026(May 20-22)」Exhibition Information
2026.03.04
「CPHI Japan 2026(April 21-23)」Exhibition Information
2026.03.02
[Research Achievement] Research result on a novel [2+2+1] radical annulation reaction enabled by 3D ED/MicroED have b...
2026.04.02
How We Overcame API Shortages and Tight Development Timelines in Early Clinical Stages - Xcelodose® Utilization Case...
2026.03.06
SPERA PHARMA’s Structural Analysis Capabilities Integrating 3D ED / MicroED Technology
2021.02.26
Contributing to efficient API process development using asymmetric synthesis technology
2017.09.13
Control of Potential Mutagenic Impurities: PMIs
page top